One year ago, after being burned by disappointing sales of drugs like Dendreon Corp.’s Provenge and Human Genome Sciences Inc.’s Benlysta, investors swore off biotechs in the midst of a commercial launch. The savvy strategy was to make money selling biotech stocks at the inflection point of drug approval rather than betting on a drug’s longer-term commercial potential, and “short the launch” became the mantra of the day.
But over the last 12 months, biotech has been cranking out new drugs, and a few have gotten off to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?